<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36379394</PMID><DateCompleted><Year>2022</Year><Month>12</Month><Day>16</Day></DateCompleted><DateRevised><Year>2022</Year><Month>12</Month><Day>22</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1095-953X</ISSN><JournalIssue CitedMedium="Internet"><Volume>175</Volume><PubDate><Year>2022</Year><Month>Dec</Month></PubDate></JournalIssue><Title>Neurobiology of disease</Title><ISOAbbreviation>Neurobiol Dis</ISOAbbreviation></Journal><ArticleTitle>C9orf72 repeat length might influence clinical sub-phenotypes in dementia patients.</ArticleTitle><Pagination><StartPage>105927</StartPage><MedlinePgn>105927</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.nbd.2022.105927</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0969-9961(22)00319-9</ELocationID><Abstract><AbstractText Label="BACKGROUND">C9orf72 repeat expansions have been observed in a wide variety of neurodegenerative disorders. The cut-off between normal and pathogenic alleles is not well established as repeat sizing methods are often semi-quantitative. However, intermediate alleles might influence disease prevalence and phenotype, as seen for other repeat expansion disorders. We aimed to further delineate the prevalence of small, intermediate and expanded C9orf72 alleles and elucidate their potential influence on the disease phenotype.</AbstractText><AbstractText Label="METHODS">DNA derived from patients (n&#xa0;=&#xa0;1804) and healthy individuals (n&#xa0;=&#xa0;643) was obtained from multiple collectives in Austria. Genotyping was performed using a two-step PCR assay followed by Southern blotting.</AbstractText><AbstractText Label="RESULTS">3.4% of clinically diagnosed frontotemporal dementia (FTD; n&#xa0;=&#xa0;5/147) cases and 0.8% of clinically diagnosed Alzheimer's disease (AD; n&#xa0;=&#xa0;5/602) cases were carriers of a pathological C9orf72 repeat expansion. A significantly earlier disease onset was detected in expansion carriers compared to non-carriers in the FTD and AD cohorts (median 50&#xa0;years, range 39-64 vs. median 64&#xa0;years, range 36-92, p&#xa0;=&#xa0;0.018 and median 63&#xa0;years, range 54-71 vs. median 74&#xa0;years, range 45-92, p&#xa0;=&#xa0;0.006, respectively). C9orf72 intermediate alleles were significantly associated with cerebellar symptoms (p&#xa0;=&#xa0;0.0004) and sensory deficits in the dementia cohort (p&#xa0;=&#xa0;0.01).</AbstractText><AbstractText Label="CONCLUSIONS">C9orf72 repeat expansion carriers showed earlier disease onset compared to non-carriers with clinical diagnosis of FTD and AD. Furthermore, C9orf72 intermediate repeats might modify the phenotypic expression in dementia.</AbstractText><CopyrightInformation>Copyright &#xa9; 2022 The Authors. Published by Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>K&#xf6;nig</LastName><ForeName>Theresa</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Neurology, Medical University of Vienna, 1090 Vienna, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wurm</LastName><ForeName>Raphael</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Neurology, Medical University of Vienna, 1090 Vienna, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Parvizi</LastName><ForeName>Tandis</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Neurology, Medical University of Vienna, 1090 Vienna, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Silvaieh</LastName><ForeName>Sara</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Neurology, Medical University of Vienna, 1090 Vienna, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hotzy</LastName><ForeName>Christoph</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Neurology, Medical University of Vienna, 1090 Vienna, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cetin</LastName><ForeName>Hakan</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Neurology, Medical University of Vienna, 1090 Vienna, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Klotz</LastName><ForeName>Sigrid</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Division of Neuropathology and Neurochemistry, Department of Neurology, Medical University of Vienna, 1090 Vienna, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gelpi</LastName><ForeName>Ellen</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Division of Neuropathology and Neurochemistry, Department of Neurology, Medical University of Vienna, 1090 Vienna, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bancher</LastName><ForeName>Christian</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Neurology, Landesklinikum Horn-Allentsteig, 3580, Horn, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Benke</LastName><ForeName>Thomas</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Neurology, Medical University of Innsbruck, 6020 Innsbruck, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dal-Bianco</LastName><ForeName>Peter</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Neurology, Medical University of Vienna, 1090 Vienna, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Defrancesco</LastName><ForeName>Michaela</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Psychotherapy and Psychosomatics, Medical University of Innsbruck, 6020 Innsbruck, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fischer</LastName><ForeName>Peter</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Danube Hospital Vienna, 1220 Vienna, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Marksteiner</LastName><ForeName>Josef</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Psychotherapy A, Landesklinikum Hall, 6060 Hall in Tirol, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sutterl&#xfc;ty</LastName><ForeName>Hedwig</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Institute of Cancer Research, Department of Medicine I, Medical University of Vienna, 1090 Vienna, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ransmayr</LastName><ForeName>Gerhard</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Neurology 2, Medical Faculty, Johannes Kepler University, 4040 Linz, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schmidt</LastName><ForeName>Reinhold</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Neurology, Medical University of Graz, 8036 Graz, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zimprich</LastName><ForeName>Alexander</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Neurology, Medical University of Vienna, 1090 Vienna, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>St&#xf6;gmann</LastName><ForeName>Elisabeth</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Neurology, Medical University of Vienna, 1090 Vienna, Austria. Electronic address: elisabeth.stoegmann@meduniwien.ac.at.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>11</Month><Day>13</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Neurobiol Dis</MedlineTA><NlmUniqueID>9500169</NlmUniqueID><ISSNLinking>0969-9961</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000073885">C9orf72 Protein</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011506">Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C568651">C9orf72 protein, human</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D042622" MajorTopicYN="N">DNA Repeat Expansion</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000073885" MajorTopicYN="N">C9orf72 Protein</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D057180" MajorTopicYN="Y">Frontotemporal Dementia</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011506" MajorTopicYN="N">Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010641" MajorTopicYN="N">Phenotype</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Alzheimer dementia (AD)</Keyword><Keyword MajorTopicYN="N">C9orf72 hexanucleotide repeat expansion</Keyword><Keyword MajorTopicYN="N">Disease modifier</Keyword><Keyword MajorTopicYN="N">Early onset dementia</Keyword><Keyword MajorTopicYN="N">Frontotemporal dementia (FTD)</Keyword><Keyword MajorTopicYN="N">Intermediate repeats</Keyword><Keyword MajorTopicYN="N">Neurodegenerative diseases</Keyword></KeywordList><CoiStatement>Conflict of interest statement For the present study, SE received support from Roche and RG from the Jubilee Funds of the Austrian National Bank. In the past 36&#xa0;months, SE received grants from Roche, FFG/AAL, Horizon2020 and the Austrian Alzheimer Association (all to the institution), CH from Roche and Novartis, SK from the Hochschuljubil&#xe4;umsfonds, RG and SR from the Austrian Science Fund. SE received consulting fees from Biogen, WR from Alnylam Austria, BC from Roche Austria, RG from Abbvie, Alpine Market Research, Gr&#xfc;nenthal, Novartis, Ratiopharm, Roche, Sanofi Aventis, Stada and UBC, SR from Axon Neuroscience, Roche and Biogen. For lectures, presentations, speakers bureaus, manuscript writing, or educational events payment was received by SE (Biogen, Roche, Eisai), WR (Pfizer), GE (Sanofi), BC (Schwabe), DM and RG (MedAhead). GE received payment for expert testimony from the Medical University of Vienna. BC received support for the Landesklinikum Horn for attending meetings from Genzyme. WR issued a patent for means and methods for the early prediction of poor neurological outcome in out-of-hospital cardiac arrest survivors. SE participated on an advisory board (Aboard Biogen, Roche), as well as CH (Roche), GE (IDIBAPS), BC (Roche), DBP (Roche), DM and SR (Rymind, no payment). GE held leadership or a fiduciary role in scientific societies (unpaid), SE in the Austrian Alzheimer Association, the EAN scientific panel dementia and in the steering committee DACh Tagung Biogen, BC in the Austrian Alzheimer Association (vize president). None of the authors received royalties or licences, held stock or stock options in entities related to the current manuscript, received equipment, materials, drugs, medical writing, gifts, or other services or had other financial or non-financial interests in the past 36&#xa0;months. KT, PT, SS, HC, BT, FP, MJ, SH and ZA have nothing to disclose.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>6</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>10</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>11</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>11</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>12</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>11</Month><Day>15</Day><Hour>19</Hour><Minute>26</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36379394</ArticleId><ArticleId IdType="doi">10.1016/j.nbd.2022.105927</ArticleId><ArticleId IdType="pii">S0969-9961(22)00319-9</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>